Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2486302 | Journal of Pharmaceutical Sciences | 2006 | 10 Pages |
Abstract
We report the preparation and the immunogenicity of a conjugate vaccine obtained by chemically conjugating a variant of the extracellular peptide fragment of influenza type A M2 protein to the human papillomavirus (HPV) viruslike particle (VLP). Conjugates comprised of approximately 4000 copies of the antigenic peptide per VLP are obtained as the result of the reaction between a C-terminal cysteine residue on the peptide and the maleimide-activated HPV VLP. The resulting conjugates have an average particle size slightly larger than the carrier and present enhanced overall stability against chemical and thermal-induced denaturation. The M2-HPV VLP conjugates lost the binding affinity for anti-HPV conformational antibodies but retained reactivity to a M2-specific monoclonal antibody. The conjugate vaccine formulated with aluminum adjuvant and delivered in two doses of 30-ng peptide was found to be highly immunogenic and conferred good protection against lethal challenge of influenza virus in mice. These results suggest that HPV VLP can be used as a carrier for synthetic or small antigens for the development of subunit vaccines. © 2005 Wiley-Liss, Inc. and the American Pharmacists Association
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Drug Discovery
Authors
Roxana M. Ionescu, Craig T. Przysiecki, Xiaoping Liang, Victor M. Garsky, Jiang Fan, Bei Wang, Robert Troutman, Yvette Rippeon, Elizabeth Flanagan, John Shiver, Li Shi,